-->

Ad Unit (Iklan) BIG

Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026; COVID-19 Pandemic to Have Moderate Impact on Market Growth

Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026; COVID-19 Pandemic to Have Moderate Impact on Market Growth Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017


source https://www.openpr.com/news/2224889/pegfilgrastim-biosimilar-market-to-exhibit-10-cagr-through

Related Posts

Subscribe Our Newsletter